Mckesson (MCK) Stock
Major pharmaceutical distributor supplying medicines to hospitals and pharmacies. Here's the price, business snapshot, and what's worth knowing about Mckesson in August 2026.
McKesson Corporation (ticker: MCK) is one of the world’s largest pharmaceutical distributors and healthcare services providers, supplying medicines, medical products and technology solutions to pharmacies, hospitals and manufacturers. With a market capitalisation of about $97.93B, McKesson operates a scale-driven business that benefits from recurring, high-volume flows but typically operates on thin distribution margins. Key investor considerations include exposure to the US healthcare system, sensitivity to drug pricing and reimbursement changes, ongoing regulatory and litigation risk, and the company’s push into specialty drugs, automation and software services that can lift profitability over time. McKesson historically generates significant cash flow and has returned capital to shareholders, but inventory- and working-capital intensity can create earnings volatility. This summary is for general, educational purposes only and not personal financial advice; values can fall as well as rise and suitability depends on individual circumstances.
Why It’s Moving
McKesson is rallying on strong earnings and a strategic deal, but analysts still see limited room to run.
- McKesson’s latest quarter beat expectations and management lifted full-year profit guidance, signaling that its core pharmacy and specialty-drug businesses are still growing faster than expected.
- The company also announced a $2.25 billion deal for Precision Medicine Group, underscoring a push deeper into oncology and clinical research services, which investors view as a strategic expansion beyond distribution.
- The stock’s warning tone appears tied to valuation: after the recent run-up on strong earnings and deal enthusiasm, analysts are highlighting limited upside and a near-term downside risk if momentum cools.
McKesson is rallying on strong earnings and a strategic deal, but analysts still see limited room to run.
- McKesson’s latest quarter beat expectations and management lifted full-year profit guidance, signaling that its core pharmacy and specialty-drug businesses are still growing faster than expected.
- The company also announced a $2.25 billion deal for Precision Medicine Group, underscoring a push deeper into oncology and clinical research services, which investors view as a strategic expansion beyond distribution.
- The stock’s warning tone appears tied to valuation: after the recent run-up on strong earnings and deal enthusiasm, analysts are highlighting limited upside and a near-term downside risk if momentum cools.
Sixth Month Growth Performance
next-earnings-question
McKesson’s next earnings date is expected to be November 4, 2026, after the market close. The report should cover fiscal Q2 2027 results. This timing follows the company’s established quarterly reporting pattern, though the date has not yet been formally confirmed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying McKesson's stock with a target price of $948.67, indicating strong growth potential.
Financial Health
McKesson demonstrates solid cash flow and revenue, indicating strong business operations and financial stability.
Dividend
McKesson's dividend yield of 0.43% is relatively low, indicating limited dividend income for investors. If you invested $1000 you would be paid $4.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Scale & Reach
McKesson’s size delivers stable volumes and negotiating power, though low distribution margins mean scale doesn’t remove commercial or regulatory risk.
Technology Shift
Investment in automation and software could improve efficiency and margins over time, but returns depend on successful execution and adoption.
Policy & Regulation
Changes in drug pricing, reimbursement or legal outcomes can materially affect performance, so monitor regulatory developments closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
